TLDR
- Artelo Biosciences (ARTL) stock jumped more than 200% on Wednesday.
- The rally followed a new patent filing for obesity drug candidate ART27.13.
- The patent covers ART27.13 alone and combined with GLP-1 drugs like semaglutide.
- Mouse study data showed 40% weight loss when ART27.13 was paired with semaglutide.
- ARTL remains down 59% year-to-date despite the one-day spike.
Artelo Biosciences (ARTL) stock surged more than 200% on Wednesday, trading as high as $12.20 before settling near a 206% daily gain. The move came after the clinical-stage biopharmaceutical company filed a new provisional patent application for its drug candidate ART27.13.
Artelo Biosciences, Inc., ARTL
The patent covers ART27.13 as a standalone treatment for obesity. It also covers the drug when combined with GLP-1 receptor agonists, including semaglutide.
The filing followed fresh data from the company’s DIO-2 obesity study in mice. That data built on results first shared on September 16.
What the Study Found
Over four weeks, ART27.13 alone produced about 20% weight loss in obese mice. That result was close to what semaglutide alone delivered.
When researchers combined ART27.13 with semaglutide, mice lost about 40% of their body weight. Roughly 80% of that weight loss came from fat mass in the ART27.13 groups, compared to about 70% for semaglutide alone.
The combination also improved how the mice processed sugar. It suppressed appetite and led to higher bone mineral density, an area of growing concern for GLP-1 drugs on the market today.
Both drugs lowered total cholesterol, LDL and HDL levels. The combination produced larger drops than either drug alone. Liver size also decreased across every treatment group.
Management Response
CEO Gregory Gorgas called the findings unexpected. He said they could expand the opportunity for ART27.13 beyond the company’s original hypothesis.
Gorgas pointed to the bone density increase as a standout result. He noted it matters given industry worries about bone and muscle loss during standard GLP-1 treatment.
He added that the drug’s potential to boost an existing GLP-1 therapy, while also working as a standalone treatment, opens a new development path. The company intends to protect that path as research continues.
ART27.13 works on two cannabinoid receptors, CB1 and CB2, located outside the brain. In lean mice, the drug showed no effect on key metabolic tests. Artelo said that gap may point to a role tied specifically to body fuel use rather than general drug activity.
The company has already built a human safety data set. It includes results from six past trials, two ongoing trials and close to 300 people who have received the drug.
Trading volume told its own story on Wednesday. More than 10 million ARTL shares changed hands, compared to a three-month average of roughly 95,000 shares per day.
Despite the spike, ARTL stock remains down 59% for the year. It has fallen 97% over the past 12 months.
The company said it plans further research into why ART27.13 produces these effects, particularly its impact on fat mass and bone density when paired with GLP-1 therapies.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions β all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
